GLPwatch

Protective effects of pioglitazone and/or liraglutide on pancreatic β-cells in db/db mice: Comparison of their effects between in an early and advanced stage of diabetes.

Mol Cell Endocrinol · 2015

Last updated 2026-05-28

In a study on diabetic mice, the drugs pioglitazone and liraglutide improved insulin production and β-cell function when given early in diabetes but not in advanced stages. The treatments increased β-cell mass and reduced cell death only when started early, with no effects observed in later stages.

AI summary of the abstract below.

JournalMol Cell Endocrinol, 2015
Citations54
Relative citation ratio1.95
NIH percentile73
Molecules liraglutide
Conditions studied Type 2 Diabetes

Abstract

The aim was to compare the protective effects of pioglitazone (PIO) and/or liraglutide (LIRA) on β-cells with the progression of diabetes. Male db/db mice were treated with PIO and/or LIRA for 2 weeks in an early and advanced stage. In an early stage insulin biosynthesis and secretion were markedly increased by PIO and LIRA which was not observed in an advanced stage. In concomitant with such phenomena, expression levels of various β-cell-related factors were up-regulated by PIO and LIRA only in an early stage. Furthermore, β-cell mass was also increased by the treatment only in an early stage. Although there was no difference in apoptosis ratio between the two stages, β-cell proliferation was augmented by the treatment only in an early stage. In conclusion, protective effects of pioglitazone and/or liraglutide on β-cells were more powerful in an early stage of diabetes compared to an advanced stage.

Verbatim abstract via PubMed 25463759 ↗

Related research